Literature DB >> 1381311

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.

N Lycke1, T Tsuji, J Holmgren.   

Abstract

This study addressed the question of whether the mucosal adjuvant property of cholera toxin (CT) and the structurally closely related Escherichia coli heat-labile toxin (LT) requires the enterotoxic and adenylate cyclase/cAMP activating property of these molecules. Therefore, we investigated the cytotoxic and adjuvant abilities of the enterotoxins and compared the results with those obtained with the non-toxic CT and LT derivatives; recombinant CTB (rCTB) and a mutated LT (mLT), which had a single amino acid substitution in position 112 (Glu----Lys) of the A subunit. Detailed functional studies revealed that, in contrast to the enterotoxins, both rCTB and mLT lacked ADP-ribosylating and cAMP-stimulating abilities. However, similar membrane ganglioside GM1-receptor binding ability of all the putative adjuvants was demonstrated. When the probe antigen, keyhole limpet hemocyanin (KLH), was given perorally together with CT or LT strong gut mucosal anti-KLH immune responses were stimulated, whereas no or very low anti-KLH responses were seen in the groups which received antigen admixed with rCTB or the mLT. Moreover, the specific serum antibody responses to the various immunization protocols closely paralleled the local anti-KLH response in the gut. From these results it appears that the adjuvant mechanism of LT, and probably also of CT, is linked to the ability to ADP-ribosylate and to stimulate cAMP formation. However, this study does not unequivocally rule out other possibilities such as interactions by the A1 fragment of CT or LT with other G-proteins than Gs alpha or events that parallel or precede the effects on the adenylate cyclase/cAMP system. Thus, the levels of ADP-ribosylation and cAMP-induction that are required and the key event or target cell that is responsible for the adjuvant effect of CT and LT remain to be elucidated. Studies are underway to address these issues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381311     DOI: 10.1002/eji.1830220915

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  80 in total

1.  Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells.

Authors:  K Eriksson; I Nordström; C Czerkinsky; J Holmgren
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; Jarrod L Erbe; C Virginia Lockatell; David E Johnson; Michael G Jobling; Randall K Holmes; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

6.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

7.  Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.

Authors:  A Lee; M Chen
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.